



Perinatal Services BC
An agency of the Provincial Health Services Authority

Legalization of cannabis: Implications for maternal and infant health in BC and emerging best practice for response

Health Mothers Healthy Babies Conference
Vancouver, BC
March 1st, 2018

Sabrina Luke, PhD
Epidemiologist, Perinatal Services BC



Legalization of Cannabis in Canada

- Cannabis currently a Schedule II drug under the Controlled Drug and Substances Act.
- Cannabis Act (Bill C-45) introduced in 2017.
- Subject to parliamentary approval, cannabis could be legalized in Canada by July 2018.
- Recommendations for use in pregnancy?

Trends of cannabis use in Canada

- Canada has one of the highest rates of cannabis use among youth in the world.
- Cannabis use among Canadian women increased from 7.4% in 2013 to 9.7% in 2015.
- Cannabis is the most common illicit drug used by pregnant women.

Potential implications


- Nearly half of pregnancies in Canada are unplanned.
- Cannabinoids cross the placenta with greater transfer in early pregnancy.
- Potential for fetal exposure in the first trimester before women know they are pregnant.

PDR Data Analysis

Objectives

- To examine the trends of cannabis use among pregnant women in BC and related maternal characteristics.
- To determine the association between cannabis use in pregnancy and perinatal outcomes among women in BC including:
 - Stillbirth (antepartum and intrapartum)
 - Spontaneous preterm birth
 - Small-for-gestational age

Perinatal Data Registry (PDR)



Antenatal Form

8. Lifestyle & Social

| <i>Discussed</i> | <i>Concerns</i> | <i>Referred</i> |
|--|-----------------|--------------------------|
| <input type="checkbox"/> Diet/Food Safety _____ | | <input type="checkbox"/> |
| <input type="checkbox"/> Folic acid _____ | | |
| <input type="checkbox"/> Physical Activity/rest/work _____ | | <input type="checkbox"/> |
| <input type="checkbox"/> OTC drugs/vitamins _____ | | <input type="checkbox"/> |
| <input type="checkbox"/> Alcohol <input type="checkbox"/> never <input type="checkbox"/> quit (DD/MM/YYYY) _____ | | |
| Drinks/wk: before pregnancy _____ current _____ | | |
| Binge drinking <input type="checkbox"/> No <input type="checkbox"/> Yes | | <input type="checkbox"/> |
| <input type="checkbox"/> TWEAK score _____ (see reverse) | | |
| <input type="checkbox"/> Substance use <input type="checkbox"/> No <input type="checkbox"/> Yes | | <input type="checkbox"/> |
| <input type="checkbox"/> Heroin <input type="checkbox"/> Cocaine <input type="checkbox"/> Marijuana | | |
| <input type="checkbox"/> Methadone <input type="checkbox"/> Solvents <input type="checkbox"/> Other | | |
| <input type="checkbox"/> Prescription <input type="checkbox"/> Unknown _____ | | |
| <input type="checkbox"/> Smoking <input type="checkbox"/> never <input type="checkbox"/> quit (DD/MM/YYYY) _____ | | |
| Cig/day: before pregnancy _____ current _____ | | <input type="checkbox"/> |
| <input type="checkbox"/> Exposure 2nd hand smoke <input type="checkbox"/> No <input type="checkbox"/> Yes | | |



Methods

- Time period: April 1st, 2008 to March 31st, 2016.
- Excluded records:
 - missing data on outcomes and gestational age
 - gestational ages less than 20 weeks or greater than 44 weeks.
- Singleton births

Methods

- Trends of cannabis use among pregnant women in BC.
- Chi-square analysis of maternal characteristics and cannabis use.
- Logistic Regression:
 - Association between cannabis use and small-for-gestational age (<10th) and spontaneous preterm birth (<37 weeks).
- Cox Proportional Hazards Model:
 - Cannabis use and stillbirth
 - Ran separate models for overall stillbirth, antepartum and intrapartum
 - Excluded late termination


Methods

- Logistic regressions and Cox proportional hazards models adjusted for:
 - maternal age
 - maternal ethnicity (Nam Pehchan)
 - SES (QAIPPE)
 - pre-pregnancy BMI
 - tobacco use in pregnancy
 - alcohol use in pregnancy
 - illicit substances (cocaine, heroin/opioids, solvents, designer drugs, methadone, hallucinogens, stimulants, prescription medication, non-prescription medication, other unknown drug)
- Cox proportional hazards models also adjusted for any chromosomal or congenital anomalies.



Results: Trends of cannabis use in BC

- Cannabis use among pregnant women in BC has increased over the past decade.



Results: Maternal characteristics and cannabis use

| Maternal Characteristics | Cannabis Use N=5801 | No Cannabis Use N=237339 | p-value |
|----------------------------------|------------------------|-----------------------------|---------|
| Maternal age | | | <0.0001 |
| 10-24 | 49.8 | 14.6 | |
| 25-29 | 25.7 | 27.9 | |
| 30-34 | 16.8 | 34.2 | |
| 35-39 | 6.6 | 19.1 | |
| 40+ | 1.2 | 4.4 | |
| Neighborhood SES (QAIPPE) | | | <0.0001 |
| 1 - Lowest | 34.1 | 21.0 | |
| 2 | 22.3 | 21.3 | |
| 3 | 18.0 | 20.9 | |
| 4 | 15.7 | 20.5 | |
| 5 – Highest | 10.0 | 16.3 | |
| Tobacco use | 69.6 | 16.6 | <0.0001 |
| Any alcohol use | 12.1 | 0.9 | <0.0001 |
| Other substance use | 15.8 | 0.9 | <0.0001 |
| History of anxiety | 17.9 | 6.5 | <0.0001 |
| History of depression | 28.7 | 9.6 | <0.0001 |
| History mental illness | 41.1 | 15.7 | <0.0001 |

Results: Maternal characteristics and cannabis use

| Maternal Characteristics | Cannabis Use N=5801 | No Cannabis Use N=237339 | p-value |
|----------------------------------|------------------------|-----------------------------|---------|
| Maternal age | | | <0.0001 |
| 10-24 | 49.8 | 14.6 | |
| 25-29 | 25.7 | 27.9 | |
| 30-34 | 16.8 | 34.2 | |
| 35-39 | 6.6 | 19.1 | |
| 40+ | 1.2 | 4.4 | |
| Neighborhood SES (QAIPPE) | | | <0.0001 |
| 1 - Lowest | 34.1 | 21.0 | |
| 2 | 22.3 | 21.3 | |
| 3 | 18.0 | 20.9 | |
| 4 | 15.7 | 20.5 | |
| 5 – Highest | 10.0 | 16.3 | |
| Tobacco use | 69.6 | 16.6 | <0.0001 |
| Any alcohol use | 12.1 | 0.9 | <0.0001 |
| Other substance use | 15.8 | 0.9 | <0.0001 |
| History of anxiety | 17.9 | 6.5 | <0.0001 |
| History of depression | 28.7 | 9.6 | <0.0001 |
| History mental illness | 41.1 | 15.7 | <0.0001 |

Results: Maternal characteristics and cannabis use

| Maternal Characteristics | Cannabis Use N=5801 | No Cannabis Use N=237339 | p-value |
|----------------------------------|------------------------|-----------------------------|---------|
| Maternal age | | | <0.0001 |
| 10-24 | 49.8 | 14.6 | |
| 25-29 | 25.7 | 27.9 | |
| 30-34 | 16.8 | 34.2 | |
| 35-39 | 6.6 | 19.1 | |
| 40+ | 1.2 | 4.4 | |
| Neighborhood SES (QAIPPE) | | | <0.0001 |
| 1 - Lowest | 34.1 | 21.0 | |
| 2 | 22.3 | 21.3 | |
| 3 | 18.0 | 20.9 | |
| 4 | 15.7 | 20.5 | |
| 5 – Highest | 10.0 | 16.3 | |
| Tobacco use | 69.6 | 16.6 | <0.0001 |
| Any alcohol use | 12.1 | 0.9 | <0.0001 |
| Other substance use | 15.8 | 0.9 | <0.0001 |
| History of anxiety | 17.9 | 6.5 | <0.0001 |
| History of depression | 28.7 | 9.6 | <0.0001 |
| History mental illness | 41.1 | 15.7 | <0.0001 |

Results: Perinatal outcomes and cannabis use

| Perinatal outcomes | Cannabis Use N=5801 | No Cannabis Use N=237339 | p-value |
|--|------------------------|-----------------------------|---------|
| Small-for-gestational age (<10 th percentile) | 10.1 | 6.5 | <0.0001 |
| Large-for-gestational age | 10.0 | 12.7 | <0.0001 |
| Spontaneous preterm birth | 7.5 | 4.3 | <0.0001 |
| Stillbirth | 0.5 | 0.3 | 0.0001 |
| Antepartum Stillbirth | 0.4 | 0.2 | <0.0001 |
| Intrapartum Stillbirth | 0.14 | 0.02 | <0.0001 |

Results: Risk for SGA, preterm birth and stillbirth

Association between cannabis use and SGA, any spontaneous preterm birth and stillbirth

| Birth Outcome | Cannabis use during pregnancy | |
|---|-------------------------------|-------------------|
| | Unadjusted OR [CI] | Adjusted OR [CI]* |
| SGA (<10th percentile) | 1.63 [1.52-1.75] | 1.48 [1.37-1.59] |
| Spontaneous Preterm Birth (<37 weeks) | 1.84 [1.70-2.00] | 1.31 [1.20-1.43] |
| | Unadjusted HR [CI] | Adjusted HR [CI]* |
| Stillbirth (All) | 1.66 [1.19-2.32] | 1.38 [0.95-1.99] |
| Antepartum Stillbirth^a | 1.47 [0.99-2.18] | 1.34 [0.88-2.06] |
| Intrapartum Stillbirth^b | 4.84 [2.33-10.1] | 2.84 [1.18-6.82] |

*Adjusted for maternal age, pre-pregnancy BMI, tobacco use, alcohol use, other substance use, QAIPPE and ethnicity.

^a Stillbirth that occurred before the onset of labour.

^b Stillbirth that occurred after the onset of labour.

Mechanisms of action

- Fetal oxygen and nutrient deprivation from altered blood supply through changes in placental vasculature.
- Changes in glucose and insulin regulation which restricts fetal growth (through insulin-like growth factors 1 and 2)?
- Similar to the effects of tobacco

Strength and Limitations

Strengths

- Large dataset that includes >99% of births in BC
- PDR data includes information on tobacco and alcohol use in pregnancy, other illicit substances and prescription medications.

Limitations

- Self-report of cannabis use, tobacco, alcohol and other substances.
- Co-occurrence of cannabis use and tobacco use.
- Alcohol use underreported and difficult to adjust for.
- Ethnicity
- Neighborhood-based index of SES

Conclusions

- Cannabis use in pregnancy and history of mental illness.
- Association between cannabis use and SGA, and spontaneous preterm birth.
- Stillbirth needs further research
- Timing of cannabis exposure, type and frequency.
- Recommendations for cannabis use in pregnancy?

References

- Wayne Hall, Louisa Degenhardt, Adverse health effects of non-medical cannabis use, In *The Lancet*, Volume 374, Issue 9698, 2009, Pages 1383-1391.
- El Marroun H, Tiemeier H, Steegers EA, et al. Intrauterine cannabis exposure affects fetal growth trajectories: the Generation R Study. *J Am Acad Child Adolesc Psychiatry* 2009;48:1173-81.
- Varner MW, Silver RM, Rowland Hogue CJ, et al. Association between stillbirth and illicit drug use and smoking during pregnancy. *Obstet Gynecol* 2014;123:113-25.
- Bolton, J, Cox, Brian, Clara, Ian, Sareen, Jitender. Use of Alcohol and Drugs to Self-Medicate Anxiety Disorders in a Nationally Representative Sample. *The Journal of Nervous and Mental Disease*. 2006;194(11):818-825.
- Lev-Ran, S., Roerecke, M., Le Foll, B., George, T., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. *Psychological Medicine*, 44(4), 797-810.
- Fretts, RC. Etiology and prevention of stillbirth. *American Journal of Obstetrics and Gynecology*. 2005; 193:1923-1935.
- Miller J, Turan S, Baschat A. Fetal growth restriction. *Seminars in perinatology*. 2008; 32(4):274-280.
- Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996Y1998. *Obstet Gynecol*. 2003;101:374Y379.
- Little BB, VanBeveren TT. Placental transfer of selected substances of abuse. *Semin Perinatol*. 1996;20:147Y153.
- Gomez, M., Hernández, M., Johansson, B., de Miguel, R., Ramos, J.A., & Fernández-Ruiz, J. (2003). Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain. *Brain Research: Developmental Brain Research*, 147(1–2), 201–207.
- Kumar, R.N., Chambers, W.A., & Pertwee, R.G. (2001). Pharmacological actions and therapeutic uses of cannabis and cannabinoids. *Anesthesia*, 56(11), 1059–1068.
- Porath-Waller, A.J. (2015). Clearing the Smoke on Cannabis: Maternal Cannabis Use during Pregnancy-An Update. Canadian Centre on Substance Abuse.